Conditions: Idiopathic Parkinson's Disease Drug Induced Dyskinesia
Keywords: Parkinson's disease dyskinesia Indonesia amantadine
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 42
Healthy volunteers: no

Brief summary:
The study will involve an eighteen-week, double-blind, placebo-controlled parallel designed comparison between add-on topiramate and add-on placebo to stable treatment with amatadine in the treatment of Parkinson's disease (PD) patients who continue to have dyskinesia on amantadine.

Detailed description:
We conducted a randomized placebo controlled trial of topiramate in PD dyskinetic subjects already on amantadine but with continuing dyskinesia. Topiramate or placebo was introduced in blinded fashion with a gradual titration (topiramate 25-150 mg/d) over 6 weeks and then a maintenance period of 8 weeks. The primary outcome of interest was change from baseline to end of study in total Unified Dyskinesia Rating Scale (UDysRS) score using Intention to Treat analysis.

Arms:
arm 1: Topiramate as adjunct to amantadine. arm 2: Placebo

Interventions: intervention 1: Topiramate intervention 2: Placebo intervention 3: Amantadine
Intervention descriptions: intervention 1: Topiramate as adjunct to amantadine intervention 2: Placebo control intervention 3: Existing treatment for all participants

Protocol document: